SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside

SK pharmteco today announced the launch of SKyvec™, its proprietary, multimodal viral vector platform. Designed to support gene therapy programs at every stage, from early research through clinical ...
Contract Pharma

SK pharmteco Launches SKyvec Platform for Multimodal Viral Vectors

SK pharmteco launched SKyvec, a viral vector platform supporting gene therapy programs, at the BIO International Convention in San Diego.
Nature

Development of a J paramyxovirus-based vaccine vector

J paramyxovirus (JPV) is a non-segmented, negative-strand RNA virus in the Jeilongvirus genus of the Paramyxoviridae family. Recently, a recombinant JPV lacking the small hydrophobic protein (SH) gene ...
GEN

Researchers’ Spinout Focuses on Simplifying Viral Vector Purification

U.S.-based researchers have developed a portfolio of peptide ligands for purifying viral vectors for gene therapies and have launched a company that develops affinity technologies for ...
Nature

Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition

To better understand the current landscape of vector manufacturing capacities, the Cellular Therapy and Immunology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation ...
Business Wire

LumaCyte Analytical Method Included in Newly Published ISO Global Standard for Viral Vector Quantification

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--LumaCyte today announced that its analytical approach has been included in the newly published International Organization for Standardization (ISO) global ...